Antitumor activity of HPA3P through RIPK3-dependent regulated necrotic cell death in colon cancer
Eugene Cho1, Jong-Kook Lee1, Eunji Park1
1Department of Biomedical Science, Chosun University, Gwangju, Korea.
Abstract:
The antimicrobial peptide HPA3 shows anticancer activity in gastric cancer and leukaemia. However, how HPA3 exerts its anticancer activity, as well as whether it also exhibits activity in other cancers, remains unknown. Therefore, the aim of this study was to evaluate the anticancer activity of HPA3 and its analogues in colon cancer and to elucidate the mechanisms responsible for this activity. HPA3P decreased cell viability, whereas HPA3 and HPA3P2 did not decrease cell viability in colon cancer cells compared with control cells. This reduction in cell viability occurred through necrosis, a conclusion supported by our observation of the release of cellular contents, our intracellular PI staining results, and our observation of the release of HMGB1. Moreover, RIPK3 inhibition blocks the reduction of cell viability by HPA3P. Consistent with this finding, we found that knocking down RIPK3 and MLKL, key necroptosis proteins, attenuates the reductions in cell viability induced by HPA3P. Furthermore, HPA3P can improve the anticancer activity of chemotherapeutic agents and exhibits anticancer activity in other cancer cells. These results suggest that HPA3P may have potential as an anticancer agent in the treatment of colon cancer.
Insights
The antimicrobial peptide HPA3P shows anticancer potential in colon cancer by inducing necrosis, a programmed cell death. This peptide enhances chemotherapy and may treat other cancers.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- The antimicrobial peptide HPA3 demonstrates anticancer effects in gastric cancer and leukemia.
- Mechanisms of HPA3's anticancer activity and its efficacy in other cancer types are largely unknown.
Purpose of the Study:
- To investigate the anticancer activity of HPA3 and its analogues in colon cancer.
- To elucidate the molecular mechanisms underlying HPA3's anticancer effects in colon cancer.
Main Methods:
- Assessing cell viability reduction in colon cancer cells treated with HPA3 and analogues.
- Investigating cell death through necrosis markers (e.g., cellular content release, PI staining, HMGB1 release).
- Evaluating the role of key necroptosis proteins (RIPK3, MLKL) using inhibition and knockdown approaches.
Main Results:
- HPA3P significantly decreased colon cancer cell viability, unlike HPA3 and HPA3P2.
- The reduction in cell viability was mediated by necrosis, evidenced by cellular content and HMGB1 release.
- Inhibition or knockdown of RIPK3 and MLKL attenuated HPA3P-induced cell death.
- HPA3P enhanced the efficacy of chemotherapeutic agents and showed activity in other cancer cell types.
Conclusions:
- HPA3P induces colon cancer cell death via necrosis, involving RIPK3 and MLKL.
- HPA3P exhibits potential as a novel anticancer agent for colon cancer treatment.
- HPA3P may serve as a valuable adjunct to chemotherapy and has broader applicability in cancer therapy.
Related Concept Videos
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Negative Regulator Molecules
The Colonization of Land
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
pH Regulation in Cells
Cytosolic pH
Under physiological conditions, the cytosolic pH is slightly more acidic than the extracellular pH. However, cells must prevent further acidification of their cytosol to...


